BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cho SH, Shim HJ, Lee SR, Ahn JS, Yang DH, Kim YK, Nam TK, Lee JJ, Kim HJ, Chung IJ. Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Dis Esophagus. 2008;21:697-703. [PMID: 18522639 DOI: 10.1111/j.1442-2050.2008.00837.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Prasad NR, Karthigeyan M, Vikram K, Parthasarathy R, Reddy KS. Palliative radiotherapy in esophageal cancer. Indian J Surg 2015;77:34-8. [PMID: 25829709 DOI: 10.1007/s12262-013-0817-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
2 Wang X, Liu X, Li D, Wang X, Huang W, Li B. Concurrent Selective Lymph Node Radiotherapy and S-1 Plus Cisplatin for Esophageal Squamous Cell Carcinoma: A Phase II Study. Ann Surg Oncol 2019;26:1886-92. [PMID: 30805810 DOI: 10.1245/s10434-019-07264-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
3 Nonoshita T, Shioyama Y, Nakamura K, Nakashima T, Ohga S, Yoshitake T, Ohnishi K, Terashima K, Asai K, Honda H. Concurrent chemoradiotherapy with S-1 for T2N0 glottic squamous cell carcinoma. J Radiat Res 2010;51:481-4. [PMID: 20601829 DOI: 10.1269/jrr.09134] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
4 Jiao Y, Shen Y, Yan H, Liu Y, Tan H, Li J. Short-term clinical effect of conformal radiotherapy combined with tegafur gimeracil oteracil potassium in treating recurrent esophagus cancer. Pak J Med Sci 2016;32:1141-5. [PMID: 27882010 DOI: 10.12669/pjms.325.10632] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Zhu LL, Yuan L, Wang H, Ye L, Yao GY, Liu C, Sun NN, Li XJ, Zhai SC, Niu LJ. A Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer. PLoS One. 2015;10:e0128616. [PMID: 26046353 DOI: 10.1371/journal.pone.0128616] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
6 Hingorani M, Dixit S, Johnson M, Plested V, Alty K, Colley P, Beavis AW, Roy R, Maraveyas A. Palliative Radiotherapy in the Presence of Well-Controlled Metastatic Disease after Initial Chemotherapy May Prolong Survival in Patients with Metastatic Esophageal and Gastric Cancer. Cancer Res Treat 2015;47:706-17. [PMID: 25687854 DOI: 10.4143/crt.2014.174] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
7 Lv S, Fang M, Yang J, Zhan W, Jia Y, Xu H, Song T. Long-term results of definitive concurrent chemoradiotherapy using S-1 in the treatment of geriatric patients with esophageal cancer. Onco Targets Ther 2016;9:5389-97. [PMID: 27660461 DOI: 10.2147/OTT.S107668] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
8 Takahashi H, Arimura Y, Yamashita K, Okahara S, Tanuma T, Kodaira J, Hokari K, Tsukagoshi H, Shinomura Y, Hosokawa M. Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol 2010;5:122-8. [PMID: 19898259 DOI: 10.1097/JTO.0b013e3181c1ffd5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
9 Bulibu J, Wang W, Tang Y, Li N, Saifuding K. Association Between Polymorphisms in the Promoter Region of microRNA-34b/c and the Chemoradiotherapy Efficacy for Locally Advanced Esophageal Squamous Cell Carcinoma in Chinese Han Population. Pathol Oncol Res 2019;25:421-7. [PMID: 29270777 DOI: 10.1007/s12253-017-0366-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
10 Chang H, Shin SK, Cho BC, Lee CG, Kim CB, Kim DJ, Lee JG, Hur J, Lee CY, Bae MK. A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer. Cancer Chemother Pharmacol. 2014;73:665-671. [PMID: 24562525 DOI: 10.1007/s00280-013-2371-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
11 Ying J, Zhang M, Qiu X, Lu Y. The potential of herb medicines in the treatment of esophageal cancer. Biomed Pharmacother. 2018;103:381-390. [PMID: 29674273 DOI: 10.1016/j.biopha.2018.04.088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
12 Cheung MC, Koniaris LG, Yang R, Zhuge Y, Mackinnon JA, Byrne MM, Franceschi D. Do all patients with carcinoma of the esophagus benefit from treatment at teaching facilities? J Surg Oncol 2010;102:18-26. [PMID: 20213687 DOI: 10.1002/jso.21509] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
13 Wang H, Li G, Chen L, Duan Y, Zou C, Hu C. Definitive concurrent chemoradiotherapy with S-1 and cisplatin in elderly esophageal squamous cell carcinoma patients. J Thorac Dis 2017;9:646-54. [PMID: 28449472 DOI: 10.21037/jtd.2017.03.105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
14 Song T, Liang X, Fang M, Wu S. High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: a systematic review and pooled analysis. Expert Rev Anticancer Ther 2015;15:1157-69. [PMID: 26235427 DOI: 10.1586/14737140.2015.1074041] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
15 Hiraki M, Tanaka M, Sato S, Kai K, Morito K, Kobayashi K, Noshiro H, Tokunaga O, Miyazaki K. A complete response in small cell carcinoma of the esophagus treated by s-1/cisplatin combined chemotherapy and radiotherapy. J Gastrointest Cancer 2010;41:275-80. [PMID: 20437111 DOI: 10.1007/s12029-010-9159-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
16 Fang M, Song T, Liang X, Lv S, Li J, Xu H, Luo L, Jia Y. Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma. Oncotarget 2017;8:37080-90. [PMID: 28415745 DOI: 10.18632/oncotarget.16180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Chen P, Zhang JY, Sha BB, Ma YE, Hu T, Ma YC, Sun H, Shi JX, Dong ZM, Li P. Luteolin inhibits cell proliferation and induces cell apoptosis via down-regulation of mitochondrial membrane potential in esophageal carcinoma cells EC1 and KYSE450. Oncotarget 2017;8:27471-80. [PMID: 28460467 DOI: 10.18632/oncotarget.15832] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 10.7] [Reference Citation Analysis]
18 Li M, Fu C, Zhang W, Huang W, Wang Z, Zhou T, Lin H, Li B. Phase I study of concurrent selective lymph node late-course accelerated hyperfractionated radiotherapy and S-1 plus cisplatin for locally advanced oesophageal squamous cell carcinoma. Br J Radiol 2016;89:20150476. [PMID: 26891913 DOI: 10.1259/bjr.20150476] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
19 Jiang XJ, Song MQ, Xin YN, Gao YQ, Niu ZY, Tian ZB. Endoscopic stenting and concurrent chemoradiotherapy for advanced esophageal cancer: A case-control study. World J Gastroenterol 2012; 18(12): 1404-1409 [PMID: 22493556 DOI: 10.3748/wjg.v18.i12.1404] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
20 Kawamoto T, Nihei K, Sasai K, Karasawa K. Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia. Int J Clin Oncol 2018;23:1076-83. [PMID: 30066207 DOI: 10.1007/s10147-018-1324-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ramakrishnaiah VP, Malage S, Sreenath GS, Kotlapati S, Cyriac S. Palliation of Dysphagia in Carcinoma Esophagus. Clin Med Insights Gastroenterol 2016;9:11-23. [PMID: 27279758 DOI: 10.4137/CGast.S30303] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
22 Wang HY, Yao ZH, Tang H, Zhao Y, Jin SL, Zhou WP, Yao SN, Yang SJ, Liu YY, Luo SX. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma. Oncotarget 2017;8:7540-7. [PMID: 27902478 DOI: 10.18632/oncotarget.13602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 So B, Marcu LG, Olver I, Gowda R, Bezak E. Cocktail without hangover: in search for the optimal chemotherapy in the combined management of non-operable esophageal carcinomas. Acta Oncologica 2017;56:899-908. [DOI: 10.1080/0284186x.2017.1307518] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Ikeda E, Kojima T, Kaneko K, Minashi K, Onozawa M, Nihei K, Fuse N, Yano T, Yoshino T, Tahara M, Doi T, Ohtsu A. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. Jpn J Clin Oncol 2011;41:964-72. [PMID: 21742654 DOI: 10.1093/jjco/hyr088] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
25 Yang J, Wang T, Qiu M, Li Q. Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer: Advanced inoperable oesophageal cancer. Intern Med J 2015;45:757-61. [DOI: 10.1111/imj.12773] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
26 Yoon DH, Jang G, Kim JH, Kim YH, Kim JY, Kim HR, Jung HY, Lee GH, Song HY, Cho KJ, Ryu JS, Kim SB. Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2015;91:489-96. [PMID: 25680595 DOI: 10.1016/j.ijrobp.2014.11.019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]